2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma

Mark Hoffman*, Martin S. Tallman, David Hakimian, Dale Janson, Denise Hogan, Daina Variakogis, Timothy Kuzel, Leo I. Gordon, Kanti Rai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

81 Scopus citations


Purpose: To determine the response rate to 2-chlorodeoxyadenosine (2-CdA; cladribine) in patients with advanced indolent non-Hodgkin's lymphoma (NHL) who fail to respond to or progress after a response to standard chemotherapy drugs. Patients and Methods: Twenty-one patients were treated with at least one cycle of 2-CdA 0.1 mg/kg/d by continuous infusion for 5 or 7 days. Results: The overall response rate (complete response [CR] and partial response [PR]) was nine of 21 patients (43%; 95% confidence interval, 22% to 64%). Unmaintained durable responses (longest follow-up, 29+ months) have been observed. The treatment was well tolerated by all patients. The major toxicity was related to myelosuppression (predominantly neutropenia) and immunosuppression with infection. Conclusion: The purine analog 2-CdA is an active salvage therapy in pretreated patients with indolent NHL, and deserves further assessment in untreated patients and in combination with other chemotherapy agents.

Original languageEnglish (US)
Pages (from-to)788-792
Number of pages5
JournalJournal of Clinical Oncology
Issue number4
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of '2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this